



1642  
Docket No. 53196-00002  
0968/P/JO

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Vladimir Nikolaevich PAK et al.

Serial No.: 09/885,645

Filed: June 20, 2001

§  
§  
§  
§  
§

Examiner: Susan Ungar

Group Art Unit: 1642

RECEIVED

APR 04 2003

TECH CENTER 1600/2900

For: METHOD FOR TREATMENT OF MALIGNANT NEOPLASMS AND COMPLEX  
PREPARATION HAVING ANTINEOPLASTIC ACTIVITY

BOX: NON-FEE AMENDMENT  
Commissioner for Patents  
Washington, D.C. 20231

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited postage paid with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231	
on	March 21, 2003
Signature	Lekha Gopalakrishnan

**TRANSMITTAL LETTER**

Transmitted herewith in the above-identified application are:

- 1) Response to Office Action mailed January 21, 2003- 8 pages;
- 2) Petition for Extension of Time- 2 pages;
- 3) Check in the amount of \$55; and,
- 4) Acknowledgment Postcard.

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account 10-0447 (Reference No. 53196-00002).

Docket No. 53196-00002  
0968/P/JO

Respectfully submitted on Applicant's behalf,

JENKENS & GILCHRIST,  
A Professional Corporation



---

Lekha Gopalakrishnan, Ph.D.  
Reg. No.: 46,733

Date: March 21, 2003

JENKENS & GILCHRIST,  
1445 Ross Avenue, Suite 3200  
Dallas, Texas 75202  
Tel. (214) 965-7364  
Fax (214) 855-4300

MAIL  
OIP E JCB  
APR 03 2003  
PATENT & TRADEMARK OFFICE

034 07-03  
**LASVET**

1642

**Patent and Trademark Agency**  
Established 1992

March 31, 2003

Ms. Susan Ungar  
Primary Patent Examiner  
Group Art Unit: 1642  
United States Patent and Trademark Office  
Washington, D.C. 20231  
U.S.A.

YOUR REF: 09/885,645

OUR REF: 0968/P/JO

TECH CENTER 1600/2300

APR 09 2003

RECEIVED

**Re: U.S. Patent Application No. 09/885,645 filed on June 20, 2001**  
**For: Method of treatment of malignant neoplasms and complex preparation**  
**having antineoplastic activity**

Dear Ms. Susan Ungar,

We are a Patent and Trademark Agency in Estonia, representing the applicants of the above patent application before USPTO. This is our first experience with USPTO.

We contact you directly for the reason that the response to the first Office Action filed with USPTO on October 31, 2002 remained without our explanation and objection as to the ground of rejection under MPEP § 806.05(h) arisen in the said Action. The objections, basing on MPEP § 803 and § 821.04, were not presented by us and this is not our vision of the case.

This time the response to the second Office Action filed with USPTO on March 21, 2003 has been prepared by us together with the applicants in such a form as we consider the problems under the question. The applicants have taken into account the advices and have attempted to respond to the rejections arisen.

Therefore we herewith again respectfully request you to reconsider the restriction requirement under § 806.05(h) in light of the explanations presented in the said response.

Very truly yours,

*Milvi Vänikver*  
Milvi Vänikver